Truth in the Age of Covid
Truth in the Age of Covid
Professor Greinacher has been in the forefront of the race to understand the adverse effects of the A-Z vaccine. Here is a simple explanation, and the second step, due to EDTA (ethylene diamine tetraacetic acid) is one I had not heard before. Note that EDTA is used in some …
From today’s WaPo: Of Americans not yet vaccinated, fewer than 1 in 4 people said they would be willing to get the Johnson & Johnson vaccine, a Washington Post-ABC News poll found. Confidence in the other two vaccines remained high. Emergent Solutions, which has been beaten and bloodied by the Washington Post …
A few short months ago, Emergent Biosolutions was riding high. Their stock was at $125/share. They were a $7 billion dollar company. They were the epitome of how to turn failure into success: never bringing a product they created to market selling almost exclusively to the government; selling single-source products, …
Emergent BioSolutions to be Called to Account by Congress on May 19 Read more »
As I explained in my “Flip-Flop” post, it seems that a surprising number of government authorities remain desperate to administer the A-Z vaccine, even to the older age group in which it may be only 8% efficacious or “quasi-ineffective.” Why? Why why why??? From the NY Times: The Philippines said …
Potential vaccine recipients are very fortunate that Sheryl Gay Stolberg is still on this beat at the NY Times, after twenty years. Emergent BioSolutions is a biodefense boondoggle barely pretending to be a pharmaceutical firm. No one in their right mind would want to be injected with one of their …
It is a lot worse at Emergent BioSolutions than has so far been said/ NY Times Read more »
Reminder–from my post 6 months ago: October 14: from FiercePharma: Emergent has two contracts with J&J. The first, for setup and tech transfer, is worth $135 million in 2020 and 2021. The second, for drug-substance manufacturing, will pay out $480 million in the first two years… When added to the value …
Just a reminder: Emergent gets paid well, even if clinical trials fail/Fierce Pharma Read more »
Finally the Biden administration is getting serious about Emergent BioSolutions’ Covid vaccine-making. I hope they have finally understood that this is not a company that plays by the rules. This is a company that has turned repeat failures into a multi-billion dollar business. Emergent succeeds by failing. How much extra …
A rare clotting disorder may cloud the world’s hopes for AstraZeneca’s COVID-19 vaccine By Kai Kupferschmidt, Gretchen VogelMar. 27, 2021 , 10:20 AM In the tumultuous rollout of AstraZeneca’s COVID-19 vaccine, all eyes this week were on the United States, where the company had a highly public communication breakdown over the vaccine’s efficacy with …
A man receives a dose of AstraZeneca’s COVID-19 vaccine at a conference center in Rome on 24 March. Italy halted use of the vaccine on 15 March but resumed immunizations four days later. ANTONIO MASIELLO/GETTY IMAGES A rare clotting disorder may cloud the world’s hopes for AstraZeneca’s COVID-19 vaccine …
President Joe Biden’s Visit To Emergent BioSolutions’ Baltimore Lab Canceled By Mike Hellgren March 8, 2021 BALTIMORE (WJZ) — The White House abruptly cancelled President Joe Biden’s first visit to Baltimore since taking office. Mr. Biden was scheduled to travel to Baltimore City on Wednesday to meet with executives from Merck and …
Emergent BioSolutions, a company that has never developed a product, but is famous for several very public vaccine fails and a defective nerve gas autoinjector, always gets the sweetheart deal. The US Government gave the company $628 million last year to retool their Baltimore factory (purchased in 2012 with federal funding) …